Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$470.18 14.84 (3.26%) as of 4:30 Mon 6/3


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 122.27(B)
Last Volume: 1,971,146 Avg Vol: 1,608,800
52 Week Range: $323.62 - $456.95
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 27,952 149,290 264,317 624,786
Total Sell Value $12,512,803 $62,732,519 $104,276,665 $212,070,018
Total People Sold 8 12 14 18
Total Sell Transactions 9 42 65 132
End Date 2024-03-03 2023-12-01 2023-06-02 2022-06-02

   
Records found: 3280
  Page 2 of 132  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-26 4 AS $425.70 $150,698 D/D (354) 55,804 5%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-26 4 AS $425.70 $1,804,542 D/D (4,239) 25,813 5%     
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-26 4 AS $425.70 $375,893 D/D (883) 15,972 5%     
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-26 4 AS $425.70 $2,142,974 D/D (5,034) 49,691 5%     
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-26 4 AS $425.70 $375,893 D/D (883) 7,965 5%     
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-23 4 D $431.79 $1,066,090 D/D (2,469) 58,329     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-23 4 D $431.79 $1,428,793 D/D (3,309) 56,158     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-23 4 D $431.79 $1,714,206 D/D (3,970) 30,052     -
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-23 4 D $431.79 $714,181 D/D (1,654) 16,855     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-23 4 D $431.79 $1,428,793 D/D (3,309) 36,939     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-23 4 D $431.79 $2,035,458 D/D (4,714) 54,725     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-23 4 D $431.79 $357,522 D/D (828) 8,848     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-23 4 D $431.79 $4,052,781 D/D (9,386) 136,507     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-23 4 D $431.79 $1,428,793 D/D (3,309) 53,583     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-21 4 AS $421.77 $1,519,637 D/D (3,603) 59,439 9%     
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-21 4 AS $421.77 $1,345,868 D/D (3,191) 60,798 9%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-21 4 AS $421.77 $151,837 D/D (360) 59,467 9%     
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-21 4 AS $421.77 $506,546 D/D (1,201) 18,509 9%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-21 4 AS $421.77 $1,266,154 D/D (3,002) 34,022 9%     
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-20 4 AS $420.79 $1,790,041 D/D (4,254) 63,989 8%     
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-20 4 D $420.58 $1,103,181 D/D (2,623) 68,243     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-20 4 D $420.58 $2,952,051 D/D (7,019) 145,893     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-20 4 AS $420.79 $201,979 D/D (480) 59,827 8%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-20 4 D $420.58 $1,418,616 D/D (3,373) 60,307     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-20 4 D $420.58 $1,731,948 D/D (4,118) 13,778     -
  3280 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 132
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us